– May 1, 2007
May 1, 2007
View Issues
-
Dasatinib Highly Effective for Imatinib Intolerant/Resistant CML
The prognosis for CML blast crises remains poor even with imatinib therapy. Dasatinib is an oral multi-targeted tyrosine kinase inhibitor of BCR/ABL and Src with clinical activity against imatinib-resistant CML. -
Doxil Maintenance of Ovarian Cancer Remission
There is emerging evidence that maintenance chemotherapy is of value for ovarian cancer patients after surgery and remission-induction chemotherapy. -
An Analysis of Primary Hormonal Therapy without Surgery for Elderly Patients with Operable Breast Cancer
A meta-analysis of existing data on the primary management of operable breast cancer in elderly women demonstrates that when the approach is hormonal (tamoxifen) rather than surgery, local recurrence is higher. Overall survival, however, was not different. -
CML Blast Crisis: Imatinib Plus Chemotherapy Effective for Some
In a series of 16 patients with CML blast crisis, treatment mitoxantrone, etoposide, and imatinib on four different schedules was studied in a phase I/II trial. -
Dose Dense CHOP: Not for Everybody
Dose-dense CHOP chemotherapy was compared with standard CHOP for patients with aggressive non-Hodgkin lymphoma. For young patients with low-intermediate risk disease there was improvement in response rate and survival. -
Pharmacology Watch
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years. -
Clinical Briefs in Primary Care Supplement